Condition: Advanced or Metastatic Solid Malignancies
Interventions: Drug: Sitravatinib; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Enfortumab Vedotin-Ejfv; Drug: Ipilimumab
Sponsor: Mirati Therapeutics Inc.
Recruiting
Category Archives: Clinical Trials
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Conditions: Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
Interventions: Drug: MRTX849; Drug: Docetaxel
Sponsor: Mirati Therapeutics Inc.
Recruiting
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7
Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: MRTX849 Monotherapy; Drug: MRTX849 in Combination with Pembrolizumab
Sponsor: Mirati Therapeutics Inc.
Recruiting
Study of VS-6766 + Adagrasib in KRAS G12C NSCLC Patients
Conditions: Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung; Malignant Neoplastic Disease
Intervention: Drug: VS-6766 and adagrasib
Sponsors: Verastem, Inc.; Mirati Therapeutics Inc.
Not yet recruiting
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Conditions: Recurrent Endometrial Cancer; Solid Tumors
Interventions: Drug: pembrolizumab; Drug: Sitravatinib
Sponsors: Haider Mahdi; Mirati Therapeutics Inc.
Not yet recruiting